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tion were located in Europe (N = 19), followed by Asia (N = 9),
North America (N = 7), and Oceania (N = 6). More research is
needed to determine the extent of PE education from other
sources (e.g. other disciplines and non-university based).
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Prior to patent expiry of a drug, the manufacturer will generally
increase marketing efforts in order to maintain market-share.
The introduction of generics will lead to strong competition,
forcing the original patent holder to change their marketing
strategy. These effects, together with other factors (e.g. govern-
mental price legislation) may lead to increasing drug expendi-
tures. In order to increase price competition the Dutch
government plans to modernize the drug reimbursement system,
which is conceived to inadequately control drug prices. In par-
ticular, drug prices may not relevantly decrease due to lack of
incentives for price competition. OBJECTIVES: To investigate
the magnitude of effects on market-share and drug prices, we
evaluated trends in drug volume and costs after patent expiry for
enalapril, ﬂuoxetine and ranitidine in the The Netherlands.
METHODS: Governmental price, volume and reimbursement
policies were evaluated in order to provide a framework for
developments after patent expiry. Drug use was measured as
Deﬁned Daily Doses (DDD) per 1000 population, derived from
the InterAction DataBase, comprising pharmacies in the North
of the The Netherlands. Drug costs were calculated per DDD.
Estimated trendlines for drug costs and share of drugs in the dif-
ferent trade-channels (specialité, parallel, generic) were com-
pared. RESULTS: After the patent expired, costs per DDD—for
enalapril, ﬂuoxetine and ranitidine—decreased with 61%, 51%
and 69% respectively. For enalapril and ﬂuoxetine statistical sig-
niﬁcant differences in trendlines were found. For all investigated
drugs, generic products rapidly took over the majority of the
market-share (over 75%). Nearly all new users received a generic
drug after patent expiry. Further results will be presented on
omeprazol and simvastatine, with very recent patent expiries.
CONCLUSIONS: Our ﬁndings indicate that patent expiry may
cause price competition leading to cost decreases. This is oppo-
site the current opinion that the drug reimbursement system
would inadequately control drug prices.
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OBJECTIVES: To assess the health related quality of life in
common neuromuscular disease. METHODS: The health related
quality of life (HrQol) of 73 patients (mean age: 54.0 ± 16.9;
w/m: 41 :32) with Amyotrophic Lateral Sclerosis (ALS, n = 25),
Myasthenia Gravis (MSG, n = 32) or Facioscapulohumeral Mus-
cular Dystrophy (FSHD, n = 16) has been assessed using the SF-
36 and the EQ-5D. RESULTS: Measuring the HrQol using the
EQ-5D for the three diseases the overall score differs slightly
depending on sex (female 0.79 ± 0.22, male 0.66 ± 0.29). In con-
trast the disease speciﬁc overall score for patients with ALS was
0.53 ± 0.28, with FSHD 0.78 ± 0.13 and for patients with MSG
0.87 ± 0.19. This distribution was also true for the VAS (ALS
37.5 ± 13.59 FSHD 59.06 ± 17.91, MSG 65.63 ± 24.02). The
results of the SF 36 (n = 72) subscale bodily pain and mental
health for the three subgroups were not different. Differences
were found for the subscales physical function (ALS 41 ± 31,
FSHD 45 ± 35, MSG 72 ± 29), role limitations due to physical
problems (ALS 2 ± 7, FSHD 40 ± 43, MSG 49 ± 51), general
health perceptions (ALS 31 ± 14, FSHD 52 ± 21, MSG 39 ± 49),
vitality (ALS 37 ± 15, FSHD 52 ± 21, MSG 44 ± 44), social func-
tioning (ALS 56 ± 29, FSHD 82 ± 16, MSG 81 ± 25) and role
limitations due to emotional problems (ALS 24 ± 60, FSHD 81
± 34, MSG 65 ± 58). The results that the physical functioning
of the ALS and FSHD patients are similar, but the general health
perception of the FSHD patients needs further evaluation. An
additional aspect is the strong role limitation due to emotional
problems of ALS patients. CONCLUSIONS: Neuromuscular
diseases have a considerable impact on health-related quality of
life. Patients with ALS and FSHD have diminished scores in the
EQ-5D overall score and in the VAS. The SF-36 reﬂects in more
detail the inﬂuence of the three diseases on the different dimen-
sions of health-related quality of life.
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OBJECTIVES: Patients refractory to initial anti epileptic drugs
(AEDs) monotherapy may undergo a change in their therapeu-
tic regimen. This study sought to compare the economic costs of
care of patients refractory to initial AED therapy that was not
oxcarbazepine (Trileptal®), who were switched to oxcar-
bazepine (OXC) monotherapy and who stayed on OXC for an
entire 12 months follow-up (Cohort A), compared with the costs
of the patients who failed to be on the same therapy within one
year (Cohort B). METHODS: Retrospective data from the Phar-
Metrics integrated medical and pharmacy claims database,
which includes 57 managed care plans, were analyzed. Adult
patients receiving treatment with AEDs between January 1, 2000
and March 30, 2002 were studied. Data were analyzed from 6
months prior to treatment failure with either carbamazepine,
phenytoin, or valproic acid, and through a post-therapy period
deﬁned as 12 months after switching to OXC monotherapy.
RESULTS: 169 adult patients were observed. 31.4% (53/169)
patients stayed on OXC for an entire year of follow-up, consti-
tuting Cohort A. 116 patients (Cohort B) either switched to
another drug or opted for a combination therapy at some point
within one year. Demographic and clinical characteristics were
statistically similar between cohorts. Although pre-index treat-
ment costs are similar between the two cohorts ($9434 +SD
$14,512 versus $9430 + $15,229), the mean cost of care in
Cohort A decreased by $1123 while the mean cost rose for
Cohort B during the post-failure period (p < 0.01). Post-failure
